ArunA Biomedical, Inc.

ArunA Biomedical, Inc. focuses on developing and commercializing innovative therapies using its proprietary neural exosome platform, targeting neurological diseases with its flagship product, AB126. Founded in 2003 in Athens, US, ArunA Biomedical, Inc. specializes in therapeutic exosomes.

The company has raised USD 10. 8 mn in its latest funding round in April 2021, marking its fifth deal to date. Steven Stice, the founder, has been pivotal in establishing this company, aiming to impact the field of neurology. ArunA Bio specializes in the development and commercialization of its proprietary neural exosome platform, focusing on the therapeutic exosome AB126.

This innovative product is designed to deliver multiple modes of action, including the reduction of neuro-inflammation, promotion of neuro-protection, and stimulation of neuro-regeneration. AB126 aims to address both acute neuro-conditions and chronic neurodegenerative diseases, offering significant potential benefits to patients suffering from these ailments. The target end users primarily encompass individuals with neurological diseases, alongside healthcare providers who utilize these therapies in clinical settings. Currently, Aruna Bio is actively engaged in markets across North America and Europe, where it seeks to transform treatment paradigms for millions affected by neurological disorders.

The revenue model of Aruna Bio is centered around its flagship product, AB126, which is anticipated to generate income through partnerships with healthcare institutions and direct transactions with clinical providers. The structure of these transactions involves frameworks such as B2B agreements, where healthcare facilities acquire the exosome therapy for patient treatment. Pricing strategies are based on a per-unit cost for AB126 or negotiated terms reliant on usage volume and outcomes. This approach positions Aruna Bio to build long-term relationships with clients while addressing the urgent needs of the healthcare market for effective neurological treatments.

Detailed pricing plans for AB126 and related services are aligned with industry standards, ensuring accessibility to a diverse range of healthcare stakeholders. After raising USD 10. 8 mn in venture funding in April 2021, ArunA Biomedical plans to utilize the funds to finance its business strategies until mid-2022. Future growth initiatives include advancing the development of AB126 and exploring entry into additional markets beyond North America and Europe.

Specific timelines for product launches and market expansion are still being finalized as the company seeks to enhance its footprint in the neurological therapy sector.